Suzhou, August 12, 2024 / PRNewswire/ -- CanSino Biologics Inc. (stock code: 9966.HK) announced that the latest clinical data of HER2 bispecific antibody conjugate drug (ADC) JSKN003 for the treatment of platinum-resistant ovarian cancer and advanced HER2-positive (IHC 3+) solid tumors will be presented in poster format at the European Society of Medical Oncology (ESMO) congress in 2024. The ESMO congress will be held from September 13th to 17th, 2024 in Barcelona, Spain.
Theme: A cumulative analysis of two studies of JSKN003 (a HER2-targeted antibody conjugate drug) in the treatment of platinum-resistant ovarian cancer patients.
Poster number: 759P
Live poster presentation time: Saturday, September 14, 2024
Speaker: Professor Qunxian Rao, Sun Yat-sen Memorial Hospital, Zhongshan University
Theme: The safety and efficacy of JSKN003 in the treatment of advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer)
Poster number: 675P
Live poster presentation time: Saturday, September 14, 2024
Speaker: Professor Lin Shen, Beijing Cancer Hospital, Peking University
JSKN003 is a HER2 bispecific antibody conjugate (ADC) developed independently using CanSino Biologics' unique sugar-based site-specific conjugation technology. Compared with similar ADC drugs, it has better serum stability and stronger bystander killing effect, effectively expanding the treatment window. JSKN003 has demonstrated good tolerability, safety and encouraging preliminary anti-tumor activity in two phase I clinical studies conducted in Australia and China, respectively. The two sets of data announced at the ESMO congress are derived from the cumulative analysis of two studies.
About JSKN003
JSKN003 is a HER2 bispecific antibody conjugate (ADC) developed independently using CanSino Biologics' unique sugar-based site-specific conjugation technology. Compared with similar ADC drugs, it has better serum stability and stronger bystander killing effect, effectively expanding the treatment window. Currently, multiple clinical studies of JSKN003 are underway in Australia and China, and a key clinical study on the treatment of late-stage HER2 low-expressing breast cancer in China is also actively progressing.
Concorde Jerry is an innovative biopharmaceutical company committed to discovering, developing, producing and commercializing world-class anti-tumor drugs to provide innovative biological therapies for patients. On December 12, 2019, the company was listed on the main board of the Hong Kong Stock Exchange (stock code: 9966.HK).
CanSino Biologics is an innovative biopharmaceutical company dedicated to the development, production and commercialization of world-class anti-tumor drugs, providing innovative biological therapies for patients. The Company was listed on the main board of the Hong Kong Stock Exchange on December 12, 2019 (stock code: 9966.HK).
CanSino Biologics has established biologics drug development and production technology platforms with independent intellectual property rights, such as protein/antibody engineering, antibody screening, multi-module/multi-functional antibody modification, etc. The Company has built a product pipeline with significant differentiation advantages and international competitiveness, covering innovative anti-tumor drugs such as single-domain antibodies, multi-functional antibodies and antibody conjugates. One of the products, KN035 (the first subcutaneous injection PD-(L)1 inhibitor in the world, envolimab injection, trade name: Envida), has been approved for marketing in China in 2021, making significant breakthroughs in the convenience and accessibility of cancer treatment. Three new drugs are undergoing phase III or pivotal clinical studies, and several new drugs are also in clinical stages.
"We care for patients and strive for global wellness." CanSino Biologics is focused on unmet clinical needs, continuously developing safe and effective, cost-controlled, globally competitive anti-tumor drugs to benefit patients.
Please visit the company's website: